Effects of Postoperative Radiotherapy on Leptomeningeal Carcinomatosis or Dural Metastasis after Resection of Brain Metastases in Breast Cancer Patients
2
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Purpose In this retrospective study, we compared the incidence of leptomeningeal carcinomatosis or dural metastasis (LMCDM) in patients who received whole brain radiotherapy (WBRT), partial radiotherapy (PRT), or no radiotherapy (RT) following resection of brain metastases from breast cancer. Materials and Methods Fifty-one patients with breast cancer underwent surgical resection for newly diagnosed brain metastases in two institutions between March 2001 and March 2015. Among these, 34 received postoperative WBRT (n=24) or PRT (n=10) and 17 did not. Results With a median follow-up of 12.4 months (range, 2.3 to 83.6 months), 22/51 patients developed LMCDM at a median of 8.6 months (range, 4.8 to 51.2 months) after surgery. The 18-months LMCDM-free survival (LMCDM-FS) rates were 77.5%, 30.0%, and 13.6%, in the WBRT, PRT, and no RT groups, respectively (p=0.013). The presence of a tumor adjacent to cerebrospinal fluid flow and no systemic treatment after treatment for brain metastases were also associated with poor LMCDM-FS rate. Multivariate analysis showed that WBRT compared to PRT (p=0.009) and systemic treatment (p < 0.001) were independently associated with reduced incidence of LMCDM. Conclusion WBRT improved LMCDM-FS rate after resection of brain metastases compared to PRT in breast cancer patients.
Abstract
Purpose In this retrospective study, we compared the incidence of leptomeningeal carcinomatosis or dural metastasis (LMCDM) in patients who received whole brain radiotherapy (WBRT), partial radiotherapy (PRT), or no radiotherapy (RT) following resection of brain metastases from breast cancer. Materials and Methods Fifty-one patients with breast cancer underwent surgical resection for newly diagnosed brain metastases in two institutions between March 2001 and March 2015. Among these, 34 received postoperative WBRT (n=24) or PRT (n=10) and 17 did not. Results With a median follow-up of 12.4 months (range, 2.3 to 83.6 months), 22/51 patients developed LMCDM at a median of 8.6 months (range, 4.8 to 51.2 months) after surgery. The 18-months LMCDM-free survival (LMCDM-FS) rates were 77.5%, 30.0%, and 13.6%, in the WBRT, PRT, and no RT groups, respectively (p=0.013). The presence of a tumor adjacent to cerebrospinal fluid flow and no systemic treatment after treatment for brain metastases were also associated with poor LMCDM-FS rate. Multivariate analysis showed that WBRT compared to PRT (p=0.009) and systemic treatment (p < 0.001) were independently associated with reduced incidence of LMCDM. Conclusion WBRT improved LMCDM-FS rate after resection of brain metastases compared to PRT in breast cancer patients.
참고문헌 (28)
- Barnholtz-Sloan JS, "Incidence proportions of brain metastases in patients diagnosed(1973 to 2001)in the Metropolitan Detroit Cancer Surveillance System", J Clin Oncol, 22, pp.2865~2872 (2004)
- Noordijk EM, "The choice of treatment of single brain metastasis should be based on extracranial tumor activity and age", Int J Radiat Oncol Biol Phys, 29, pp.711~717 (1994)
- Patchell RA, "A randomized trial of surgery in the treatment of single metastases to the brain", N Engl J Med, 322, pp.494~500 (1990)
- Kocher M, "Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases : results of the EORTC 22952-26001study", J Clin Oncol, 29, pp.134~141 (2011)
- Patchell RA, "Postoperative radiotherapy in the treatment of single metastases to the brain : a randomized trial", JAMA, 280, pp.1485~1489 (1998)
- Choi CY, "Stereotactic radiosurgery of the postoperative resection cavity for brain metastases : prospective evaluation of target margin on tumor control", Int J Radiat Oncol Biol Phys, 84, pp.336~342 (2012)
- Robbins JR, "Radiosurgery to the surgical cavity as adjuvant therapy for resected brain metastasis", Neurosurgery, 71, pp.937~943 (2012)
- Patel KR, "Intracranial control and radiographic changes with adjuvant radiation therapy for resected brain metastases : whole brain radiotherapy versus stereotactic radiosurgery alone", J Neurooncol, 120, pp.657~663 (2014)
- Hsieh J, "Tumor progression in patients receiving adjuvant wholebrain radiotherapy vs localized radiotherapy after surgical resection of brain metastases", Neurosurgery, 76, pp.411~420 (2015)
- Sperduto PW, "Effect of tumor subtype on survival and the graded prognostic assessment for patients with breast cancer and brain metastases", Int J Radiat Oncol Biol Phys, 82, pp.2111~2117 (2012)
- Dawood S, "Prognostic factors of survival in the trastuzumab era among women with breast cancer and brain metastases who receive whole brain radiotherapy : a single-institution review", Cancer, 116, pp.3084~3092 (2010)
- Ahn JH, "Risk for leptomeningeal seeding after resection for brain metastases : implication of tumor location with mode of resection", J Neurosurg, 116, pp.984~993 (2012)
- Dosoretz DE, "Management of solitary metastasis to the brain : the role of elective brain irradiation following complete surgical resection", Int J Radiat Oncol Biol Phys, 6, pp.1727~1730 (1980)
- Norris LK, "Neoplastic meningitis following surgical resection of isolated cerebellar metastasis : a potentially preventable complication", J Neurooncol, 32, pp.215~223 (1997)
- Brennan C, "A phase 2 trial of stereotactic radiosurgery boost after surgical resection for brain metastases", Int J Radiat Oncol Biol Phys, 88, pp.130~136 (2014)
- Chang EL, "Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation : a randomised controlled trial", Lancet Oncol, 10, pp.1037~1044 (2009)
- Regine WF, "Risk of symptomatic brain tumor recurrence and neurologic deficit after radiosurgery alone in patients with newly diagnosed brain metastases : results and implications", Int J Radiat Oncol Biol Phys, 52, pp.333~338 (2002)
- Wolfson AH, "Primary analysis of a phase II randomized trial Radiation Therapy Oncology Group(RTOG)0212 : impact of different total doses and schedules of prophylactic cranial irradiation on chronic neurotoxicity and quality of life for patients with limited-disease small-cell lung cancer", Int J Radiat Oncol Biol Phys, 81, pp.77~84 (2011)
- Huang AJ, "Risk factors for leptomeningeal carcinomatosis in patients with brain metastases who have previously undergone stereotactic radiosurgery", J Neurooncol, 120, pp.163~169 (2014)
- Ojerholm E, "Stereotactic radiosurgery to the resection bed for intracranial metastases and risk of leptomeningeal carcinomatosis", J Neurosurg, 121(Suppl), pp.75~83 (2014)
- Atalar B, "Risk of leptomeningeal disease in patients treated with stereotactic radiosurgery targeting the postoperative resection cavity for brain metastases", Int J Radiat Oncol Biol Phys, 87, pp.713~718 (2013)
- 정종명, "Incidence and Risk Factors for Leptomeningeal Carcinomatosis in Breast Cancer Patients with Parenchymal Brain Metastases", 대한신경외과학회지, 52(3), pp.193~199 (2012), 대한신경외과학회[DOI]
- Suki D, "Comparative risk of leptomeningeal disease after resection or stereotactic radiosurgery for solid tumor metastasis to the posterior fossa", J Neurosurg, 108, pp.248~257 (2008)
- Suki D, "Comparative risk of leptomeningeal dissemination of cancer after surgery or stereotactic radiosurgery for a single supratentorial solid tumor metastasis", Neurosurgery, 64, pp.664~674 (2009)
- Jo KI, "Leptomeningeal seeding in patients with brain metastases treated by gamma knife radiosurgery", J Neurooncol, 109, pp.293~299 (2012)
- Trifiletti DM, "Leptomeningeal disease following stereotactic radiosurgery for brain metastases from breast cancer", J Neurooncol, 124, pp.421~427 (2015)
- Nelson MH, "Lapatinib : a novel dual tyrosine kinase inhibitor with activity in solid tumors", Ann Pharmacother, 40, pp.261~269 (2006)
- De Ieso PB, "Breast cancer brain metastases : a 12 year review of treatment outcomes", Breast, 24, pp.426~433 (2015)